<table>
<thead>
<tr>
<th>Study</th>
<th>[reference]</th>
<th>n</th>
<th>Population</th>
<th>Age (years)</th>
<th>Men (%)</th>
<th>CVD (%)</th>
<th>FU (years)</th>
<th>Outcomes (n)</th>
<th>eGFR method</th>
<th>Adjustments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prospective cohorts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARIC, 2004 [w1;w2]</td>
<td>15006</td>
<td>Population sample</td>
<td>54</td>
<td>45</td>
<td>14</td>
<td>8.9</td>
<td>MVE (1710), Death (1325)</td>
<td>MDRD</td>
<td>BLVDSR</td>
<td></td>
</tr>
<tr>
<td>BIRNH, 2007 [w3]</td>
<td>8913</td>
<td>Population sample</td>
<td>48</td>
<td>53</td>
<td>101</td>
<td>MVE (239)</td>
<td>MDRD</td>
<td>BLSW</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMES, 2005 [w4]</td>
<td>3074</td>
<td>Population sample</td>
<td>66</td>
<td>43</td>
<td>16</td>
<td>8.2</td>
<td>MVE (224)</td>
<td>CG</td>
<td>BLVDSW</td>
<td></td>
</tr>
<tr>
<td>BRHS, 2006 [w5]</td>
<td>4029</td>
<td>Elderly men</td>
<td>69</td>
<td>100</td>
<td>19</td>
<td>6</td>
<td>MVE (304)</td>
<td>MDRD</td>
<td>BLVDSW</td>
<td></td>
</tr>
<tr>
<td>Cheng, 2008 [w6]</td>
<td>37985</td>
<td>Health screening</td>
<td>51</td>
<td>64</td>
<td>4</td>
<td>15</td>
<td>MVE (489), Death (2249)</td>
<td>MDRD</td>
<td>BLSW</td>
<td></td>
</tr>
<tr>
<td>Chien, 2008 [w7]</td>
<td>931</td>
<td>CABG</td>
<td>67</td>
<td>82</td>
<td>100</td>
<td>3.1</td>
<td>Death (94)</td>
<td>MDRD</td>
<td>BLDS</td>
<td></td>
</tr>
<tr>
<td>CHS, 2004 [w1;w2]</td>
<td>4029</td>
<td>Elderly men</td>
<td>73</td>
<td>43</td>
<td>25</td>
<td>8.0</td>
<td>MVE (710), Death (1880)</td>
<td>MDRD</td>
<td>BLVDSR</td>
<td></td>
</tr>
<tr>
<td>De Silva, 2006 [w9]</td>
<td>650</td>
<td>Stable heart failure</td>
<td>70</td>
<td>68</td>
<td>100</td>
<td>1.5</td>
<td>MVE (489), Death (2249)</td>
<td>MDRD</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>Framingham, 2004 [w1;w2]</td>
<td>6269</td>
<td>Population sample</td>
<td>54</td>
<td>46</td>
<td>12</td>
<td>8.9</td>
<td>MVE (703), Death (958)</td>
<td>MDRD</td>
<td>BLVDSR</td>
<td></td>
</tr>
<tr>
<td>Health ABC, 2008 [w10]</td>
<td>3044</td>
<td>Elderly</td>
<td>74</td>
<td>48</td>
<td>6</td>
<td>6.5</td>
<td>MVE (242)</td>
<td>MDRD</td>
<td>BLDSWR</td>
<td></td>
</tr>
<tr>
<td>Hoy, 2001 [w11]</td>
<td>794</td>
<td>Population sample</td>
<td>33</td>
<td>52</td>
<td>na</td>
<td>5.8</td>
<td>MVE (26), Death (63)</td>
<td>CG</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>JPHC, 2006 [w12]</td>
<td>3074</td>
<td>Population sample</td>
<td>66</td>
<td>43</td>
<td>16</td>
<td>8.2</td>
<td>MVE (224)</td>
<td>CG</td>
<td>BLVDSW</td>
<td></td>
</tr>
<tr>
<td>KEEP, 2007 [w13]</td>
<td>37153</td>
<td>Population sample</td>
<td>53</td>
<td>31</td>
<td>8</td>
<td>1.4</td>
<td>Death (91)</td>
<td>MDRD</td>
<td>BLSWP</td>
<td></td>
</tr>
<tr>
<td>Nippon data 90, 2006 [w18]</td>
<td>7316</td>
<td>Population sample</td>
<td>52</td>
<td>33</td>
<td>0</td>
<td>9.6</td>
<td>MVE (183), Death (655)</td>
<td>MDRD</td>
<td>BLDSW</td>
<td></td>
</tr>
<tr>
<td><strong>Regressive cohorts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amsalem, 2008 [w28]</td>
<td>3793</td>
<td>Acute heart failure</td>
<td>73</td>
<td>57</td>
<td>100</td>
<td>1</td>
<td>MVE (1072)</td>
<td>MDRD</td>
<td>BLV</td>
<td></td>
</tr>
<tr>
<td>Beddu, 2002 [w29]</td>
<td>8600</td>
<td>Coronary angiogram</td>
<td>62</td>
<td>68</td>
<td>100</td>
<td>3.2</td>
<td>MVE (657), Death (1320)</td>
<td>MDRD</td>
<td>BLVDS</td>
<td></td>
</tr>
<tr>
<td>Best, 2002 [w30]</td>
<td>5327</td>
<td>Coronary angioplasty</td>
<td>65</td>
<td>71</td>
<td>100</td>
<td>2.7</td>
<td>Death (na)</td>
<td>CG</td>
<td>VDW ††</td>
<td></td>
</tr>
<tr>
<td>Chen, 2006 [w31]</td>
<td>1609</td>
<td>Coronary angiogram</td>
<td>61</td>
<td>71</td>
<td>100</td>
<td>7</td>
<td>MVE (na), Death (382)</td>
<td>MDRD</td>
<td>BDSWR</td>
<td></td>
</tr>
<tr>
<td>Coceani, 2008 [w32]</td>
<td>1705</td>
<td>Coronary angiogram</td>
<td>55</td>
<td>80</td>
<td>100</td>
<td>10</td>
<td>MVE (222), Death (341)</td>
<td>CG</td>
<td>BLVDSWP</td>
<td></td>
</tr>
<tr>
<td>Cox, 2008 [w33]</td>
<td>33386</td>
<td>Routine blood tests</td>
<td>na</td>
<td>44</td>
<td>na</td>
<td>6</td>
<td>Death (6367)</td>
<td>MDRD</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>Dimopoulos, 2008 [w34]</td>
<td>1102</td>
<td>Congenital heart disease</td>
<td>49</td>
<td>100</td>
<td>4.1</td>
<td>MVE (103)</td>
<td>MDRD</td>
<td>none</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ezekowitz, 2004 [w35]</td>
<td>6247</td>
<td>Heart failure and CAD</td>
<td>69</td>
<td>65</td>
<td>100</td>
<td>4.3</td>
<td>Death (643)</td>
<td>CG</td>
<td>LVDS</td>
<td></td>
</tr>
<tr>
<td>Glynn, 2007 [w36]</td>
<td>1272</td>
<td>CVD on health records</td>
<td>66</td>
<td>53</td>
<td>100</td>
<td>2.9</td>
<td>MVE (170), Death (141)</td>
<td>MDRD</td>
<td>BLVDSW</td>
<td></td>
</tr>
<tr>
<td>Go, 2004 [w37]</td>
<td>1120295</td>
<td>Routine blood tests</td>
<td>52</td>
<td>45</td>
<td>6</td>
<td>2.8</td>
<td>MVE (139011), Death (51424)</td>
<td>MDRD</td>
<td>BLVDP</td>
<td></td>
</tr>
<tr>
<td>Goldberg, 2005 [w38]</td>
<td>1019</td>
<td>Acute MI</td>
<td>61</td>
<td>88</td>
<td>100</td>
<td>1</td>
<td>MVE (138)</td>
<td>MDRD</td>
<td>BVDS</td>
<td></td>
</tr>
<tr>
<td>Hillis, 2006 [w39]</td>
<td>2067</td>
<td>CABG</td>
<td>66</td>
<td>77</td>
<td>100</td>
<td>2.3</td>
<td>MVE (158)</td>
<td>MDRD</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Holzmann, 2007 [w40]</td>
<td>6575</td>
<td>CABG</td>
<td>61</td>
<td>81</td>
<td>100</td>
<td>5</td>
<td>MVE (496), Death (628)</td>
<td>CG</td>
<td>BVD</td>
<td></td>
</tr>
<tr>
<td>Hwang, 2008 [w41]</td>
<td>35529</td>
<td>Elderly health screening</td>
<td>76</td>
<td>79</td>
<td>na</td>
<td>2.5</td>
<td>MVE (328), Death (1840)</td>
<td>MDRD</td>
<td>BLDWM</td>
<td></td>
</tr>
<tr>
<td>Kangasniemi, 2008 [w42]</td>
<td>882</td>
<td>CABG</td>
<td>63</td>
<td>75</td>
<td>100</td>
<td>10.2</td>
<td>MVE (308), Death (295)</td>
<td>MDRD</td>
<td>BVDS</td>
<td></td>
</tr>
<tr>
<td>Karagiannis, 2008 [w43]</td>
<td>2291</td>
<td>Cardiac stress test</td>
<td>61</td>
<td>66</td>
<td>100</td>
<td>8</td>
<td>MVE (417), Death (553)</td>
<td>CG</td>
<td>BLVDS</td>
<td></td>
</tr>
<tr>
<td>Kontos, 2005 [w44]</td>
<td>3074</td>
<td>ACS</td>
<td>57</td>
<td>50</td>
<td>100</td>
<td>1</td>
<td>MVE (259)</td>
<td>CG</td>
<td>BD</td>
<td></td>
</tr>
</tbody>
</table>

**Table S1: Characteristics of included studies**
Kowalczyk, 2007 [w45] 1486 Acute MI ** 58 73 100 2.5 Death (208) MDRD BD
Liew, 2008 [w46] 598 PVD 69 66 100 6† Death (195) MDRD BLVDS
McAlister, 2004 [w47] 754 Stable heart failure 60† 66 100 1³ Death (203) CG BW
Mueller, 2004 [w48] 1400 ACS ** 65 71 100 1.7 Death (82) MDRD BDVS
Nikolsky, 2004 [w49] 1575 PCI + Diabetes ** 65 59 100 1³ Death (125) MDRD BVSW
O'Hare, 2005 [w50] 5787 PVD ** 69 100 100 1² Death (1289) MDRD BVDR
O'Hare, 2006 [w51] 258911 Routine blood tests 64 95 45 3.2 Death (217625) MDRD VDR
Smith, 2006 [w52] 44437 Acute MI ** 78 50 100 1³ Death (15020) MDRD BVDSR
Smith, 2008 [w53] 118753 Acute MI ** 76 51 100 10† Death (80707) MDRD BVDR
Sooklim, 2007 [w54] 1816 ACS ** 65 59 100 0.9 Death (na) MDRD BLS
Van Domburg, 2008 6447 Cardiac assessment 61 74 100 7 MVE¹ (1093), Death (2007) MDRD BLVDS

Randomised Controlled Trials

ALLHAT, 2006 [w57] 31897 Hypertension 66 54 26¹ 6¹ MVE (8537) MDRD BLVDSR
APRIS, 2006 [w58] 808 Stable CAD 59 69 100 3.4³ MVE (69) CG BVD
A to Z, 2008 [w59] 4178 ACS ** 60 75 100 2³ MVE (na) MDRD BLVDSR
BIP, 2006 [w60] 6685 Stable CAD 60 78 100 8³ MVE³ (287) CG BLVDSW
CARE, 2004 [w61] 4148 Prior MI 59 86 100 5³ MVE (592), Death (376) CG BLVDS
CHARM, 2006 [w62] 2680 Stable heart failure 65 67 100 2.9³ MVE (950), Death (625) MDRD BVDSR
DIG, 2004 [w63] 6800 Stable heart failure 64 77 100 3.1 Death (2375) MDRD BVDWR
HERS, 2001 [w64] 2761 Stable CAD 67 0 100 4.1 Death (2375) MDRD BVDWR
LIPID, 2004 [w65] 8989 Prior MI 62 83 100 6.1 MVE (1555), Death (1127) CG BLVDS
MADIT-II, 2006 [w66] 1223 Heart failure and CAD na 84 100 1.7 Death (216) MDRD VDSW
PEACE, 2006 [w66] 8280 Stable CAD 64 82 100 4.8³ MVE (696), Death (633) MDRD BVD
PRIME II, 2000 [w67] 1702 Stable heart failure 65 80 100 0.8 Death (432) MDRD BV **
PROGRESS, 2007 6071 Prior stroke or TIA 67 100 4 MVE (1058), Death (621) CG BDSW
SAVE, 2004 [w69] 2183 Acute MI ** 59 82 100 3.5 MVE (784), Death (492) MDRD BVDW
SOLVED-P, 2000 [w70] 3673 Low ejection fraction 59 89 100 3.1 Death (564) CG BVD
SOLVED-T, 2000 [w70] 2161 Heart failure 61 81 100 3.5 Death (820) CG BVD
Stent-PAMI, 2003 [w71] 847 Acute MI ** 60 75 100 1³ Death (38) CG V **
TAXUS-IV, 2005 [w72] 1300 Stable CAD 62 72 100 5³ Death (26) CG BLVDS
TRACE, 2002 [w73] 6252 Acute MI ** 68 68 100 6³ Death (~2500) CG BVDS
VA-HIT, 2004 [w74] 2505 Stable CAD 64 100 100 5.1³ MVE¹ (491) CG BLVDSW
VALLIANT, 2004 [w75] 14527 Acute MI ** 65 69 100 2.1³ MVE (5285), Death (3304) MDRD BLVDSR
VALUE, 2007 [w6] 15245 Hypertension 67 57 46 4.2 MVE (1599), Death (1127) MDRD V
WOSCOPS, 2004 [w61] 6588 High CVD risk 55 100 5³ 4.9 MVE (514), Death (240) CG BLVDS

* Adjustments, in addition to age and sex, are as follows; "B", Blood pressure or history of hypertension; "L", Plasma lipids or history of hypercholesterolaemia; "V", presence or severity of vascular disease; "D", history of diabetes; "S", smoking status; "W", weight or body mass index; "R", race; "P", proteinuria; †coronary artery disease, ‡maximum, §CVD, Cardiovascular Disease; DIG, Digitalis Intervention Group; FU, Follow-up; eGFR, Estimated Glomerular Filtration Rate; Health ABC, Cockcroft Gault creatinine clearance (ml/min); CHARM, Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity; CHS, Cardiovascular Health Study; CKD, Chronic Kidney Disease; CVD, Cardiovascular Disease; DIG, Digitalis Intervention Group; FU, Follow-up; eGFR, Estimated Glomerular Filtration Rate; Health ABC, Heart Aging and Body Composition; HERS, Heart and Estrogen/progestin Replacement Study; JPHC, Japan Public Health Centre-based study; KEEP, Kidney Early Evaluation Program; MVE, Major Vascular Events; na, not available; NHANES, National Health and Nutrition Examination Survey; NHS, Nurses Health Study; NOMAS, Northern Manhattan Study; PCI, Percutaneous Coronary Intervention; PEACE, Prevention of Events with ACE inhibition; PRIME II, Second Prospective Randomized study of Ibopamine on Mortality and Morbidity; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; SAVE, Survival And Ventricular Enlargement; SMART, Second Manifestations of ARTerial disease; SOLVED-P, Studies of Left Ventricular Dysfunction – Prevention; SOLVED-T, Studies of Left Ventricular Dysfunction – Treatment; Stent-PAMI, Stent Primary Angioplasty in Myocardial Infarction; TAXUS-IV, Fourth Paclitaxel-eluting stent trial; TIA, Transient Ischaemic Attack; TRACE, Trandolapril Cardiac Evaluation; VA-HIT, Veterans' Affairs High-Density Lipoprotein Intervention Trial; VALLIANT,Valsartan in Acute Myocardial Infarction Trial; VALUE, Valasartan Antihypertensive Long-term Use Evaluation; WHP, Worksite Hypertension Program; PVD, Peripheral Vascular Disease; WOSCOPS, West of Scotland Coronary Prevention Study.
Study references


